UBS Group
GH icon

UBS Group’s Guardant Health GH Stock Holding History

UBS Group’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Buy
+2,500
New +$272K ﹤0.01% 6418
2025
Q3 		– Sell
-30,200
Closed -$1.57M – 10528
2025
Q2 		$1.57M Buy
+30,200
New +$1.35M ﹤0.01% 5049
2024
Q2 		– Sell
-40,000
Closed -$825K – 9719
2024
Q1 		$825K Buy
+40,000
New +$857K ﹤0.01% 4754

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group's GH Position: Q2 2026 in Review

UBS Group reduced its Guardant Health (GH) stake by 38% in Q2 2026, selling an estimated $58.7M and leaving 866,046 shares worth $130M. The position accounts for 0.02% of the portfolio, ranked #945.

UBS Group first reported a position in GH in Q4 2018 and has held it in 31 quarters since. The position peaked at $175M in Q4 2025. 600 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • UBS Group held 866,046 shares of Guardant Health worth $130M as of Q2 2026.
  • UBS Group sold 539,791 Guardant Health shares in Q2 2026, an estimated $58.7M.
  • Guardant Health made up 0.02% of UBS Group's portfolio in Q2 2026, its #945 holding.
  • UBS Group first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
  • UBS Group's Guardant Health position peaked at $175M in Q4 2025.
  • 600 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.